|
Gene: SIGLEC10 |
Gene summary for SIGLEC10 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SIGLEC10 | Gene ID | 89790 |
Gene name | sialic acid binding Ig like lectin 10 | |
Gene Alias | PRO940 | |
Cytomap | 19q13.41 | |
Gene Type | protein-coding | GO ID | GO:0002250 | UniProtAcc | B7ZL06 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
89790 | SIGLEC10 | HCC1 | Human | Liver | HCC | 3.16e-16 | 1.72e+00 | 0.5336 |
89790 | SIGLEC10 | HCC2 | Human | Liver | HCC | 1.00e-24 | 1.90e+00 | 0.5341 |
89790 | SIGLEC10 | HCC5 | Human | Liver | HCC | 2.49e-20 | 1.31e+00 | 0.4932 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190303421 | Liver | HCC | regulation of response to wounding | 94/7958 | 167/18723 | 2.19e-04 | 1.66e-03 | 94 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SIGLEC10 | SNV | Missense_Mutation | novel | c.652G>A | p.Asp218Asn | p.D218N | Q96LC7 | protein_coding | deleterious(0.02) | benign(0.122) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
SIGLEC10 | SNV | Missense_Mutation | c.506N>T | p.Ala169Val | p.A169V | Q96LC7 | protein_coding | tolerated(0.1) | benign(0.304) | TCGA-AX-A06H-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD | |
SIGLEC10 | SNV | Missense_Mutation | novel | c.1094N>A | p.Gly365Asp | p.G365D | Q96LC7 | protein_coding | tolerated(0.11) | possibly_damaging(0.817) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SIGLEC10 | SNV | Missense_Mutation | c.368N>A | p.Gly123Glu | p.G123E | Q96LC7 | protein_coding | deleterious(0) | possibly_damaging(0.506) | TCGA-B5-A0K6-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SIGLEC10 | SNV | Missense_Mutation | rs376850541 | c.1768C>T | p.Arg590Trp | p.R590W | Q96LC7 | protein_coding | deleterious(0) | possibly_damaging(0.676) | TCGA-B5-A11R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
SIGLEC10 | SNV | Missense_Mutation | novel | c.99N>T | p.Glu33Asp | p.E33D | Q96LC7 | protein_coding | deleterious(0.01) | probably_damaging(0.955) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
SIGLEC10 | SNV | Missense_Mutation | novel | c.1859C>A | p.Pro620His | p.P620H | Q96LC7 | protein_coding | deleterious(0.01) | benign(0.025) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SIGLEC10 | SNV | Missense_Mutation | c.215C>T | p.Pro72Leu | p.P72L | Q96LC7 | protein_coding | tolerated(0.37) | benign(0.123) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SIGLEC10 | SNV | Missense_Mutation | novel | c.1675N>G | p.Thr559Ala | p.T559A | Q96LC7 | protein_coding | tolerated(0.28) | benign(0.001) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SIGLEC10 | SNV | Missense_Mutation | c.718G>T | p.Asp240Tyr | p.D240Y | Q96LC7 | protein_coding | deleterious(0) | possibly_damaging(0.905) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |